查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679377

胰臟癌精準醫療市場規模、佔有率、趨勢分析報告：按治療方法、診斷技術、地區和細分趨勢：2025-2030 年

Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report By Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-precision Combinations), By Diagnostic Technology, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

胰臟癌精準醫療市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，預計到2030年全球胰臟癌精準醫療市場規模將達到18.8億美元，預測期內複合年成長率為19.2%。

由於擴大採用標靶治療和免疫療法來提高存活率並最大限度地減少副作用，胰臟癌精準醫療產業正在經歷成長。先進的診斷工具，包括液態切片和分子分析，改善了早期檢測和治療結果。這種向精準醫療的轉變促進了更有效和個人化的治療策略。

技術進步，特別是次世代定序儀和生物資訊學的整合，促進了新治療標靶的發現，並實現了更有效的藥物設計。製藥公司、學術機構和政府機構加大投入，支持創新治療方法的開發。 PanCAN津貼計劃等舉措已顯示了資助胰臟癌研究的承諾，從而推動了市場成長。

受生活方式因素和人口老化的影響，胰臟癌發生率不斷上升，對專門治療的需求很高。澳洲癌症協會估計，到 2024 年，全國將診斷出 4,641 例新的胰臟癌病例。盛行率的上升促使醫療保健提供者尋求更有效的選擇，從而推動了市場的成長。此外，製藥公司和研究機構之間的策略聯盟以及監管機構的支持進一步加速了市場的成長。

胰臟癌精準醫療市場報告重點

  • 根據治療方法，標靶治療將佔據市場主導地位，到 2024 年將佔 56.0% 的佔有率。
  • 另一方面，化療和精準聯合治療預計在預測期內將以最快的複合年成長率成長。
  • 從診斷技術來看，基因組檢測將引領市場，到 2024 年將佔 40.8%。事實證明，其在識別可操作突變方面的作用對於個人化治療至關重要。
  • 液態生物檢體是一種透過 ctDNA 和 CTC 分析進行早期檢測的微創方法，由於患者治療效果的改善，預計在預測期內將以 20.3% 的最快複合年成長率成長。
  • 標靶治療和免疫治療的採用日益增多，加上先進的診斷技術，透過提高存活率和製定有效的精準醫療策略，推動了市場的成長。
  • 受高發病率和對有效治療的需求推動，北美在全球胰腺癌精準醫療行業中佔據主導地位，收入佔有率為 42.9%。
  • 胰臟癌精準醫療產業的市場參與企業包括阿斯特捷利康、輝瑞公司、諾華公司、安進公司、羅氏公司、拜耳公司、禮來公司、默克公司、梯瓦製藥工業有限公司、PharmaCyte Biotech 公司、基因泰克公司、Guardant Health、Illumina 公司、賽默飛世爾科技公司和 FOUNDATIONDICINE FOUND。
  • 2024年8月，Illumina公司為NovaSeq X系列客戶推出了新的腫瘤學菜單，以更低的成本、更大規模地為全球客戶擴展全面的基因組分析。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章胰臟癌精準醫療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析

第4章胰臟癌精準醫療市場：治療方法業務分析

  • 2024 年和 2030 年治療方法市場佔有率
  • 治療方法細分儀表板
  • 2018 年至 2030 年按治療方法分類的市場規模、預測和趨勢分析
  • 標靶治療
  • PARP 抑制劑
  • 單株抗體
  • 小分子抑制劑－EGFR抑制劑、KRAS抑制劑
  • 免疫療法
  • 免疫查核點抑制劑－PD-1抑制劑、PD-L1抑制劑
  • 癌症疫苗-GVAX、Argenpantusel-L
  • 過繼性T細胞療法-CAR-T療法
  • 精準化療組合
  • 其他

第5章胰臟癌精準醫療市場：診斷技術業務分析

  • 2024 年和 2030 年診斷市場佔有率
  • 診斷技術細分儀表板
  • 2018 年至 2030 年診斷技術市場規模、預測與趨勢分析
  • 基因組檢測
  • 分子診斷
  • 液態生物檢體
  • 基於生物標記的伴同性診斷
  • 其他（免疫組織化學（IHC）、蛋白質體學、質譜分析）

第6章 胰臟癌精準醫療市場：按地區估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 按國家/地區，2018 年至 2030 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年各國情況
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 2018-2030年各國情況
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018-2030年各國情況
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年各國情況
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • AstraZeneca
    • Pfizer Inc.
    • Novartis AG
    • Amgen Inc.
    • F. Hoffmann-La Roche Ltd
    • Bayer AG
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd
    • PharmaCyte BIoTech, Inc.
    • Genentech, Inc.
    • Guardant Health
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • FOUNDATION MEDICINE, INC.
Product Code: GVR-4-68040-526-0

Pancreatic Cancer Precision Medicine Market Growth & Trends:

The global pancreatic cancer precision medicine market size is anticipated to reach USD 1.88 billion by 2030, registering a CAGR of 19.2% during the forecast period, according to a new report by Grand View Research, Inc. The pancreatic cancer precision medicine industry experiences growth due to the increasing adoption of targeted therapies and immunotherapies, which enhanced survival rates and minimized side effects. Advanced diagnostic tools, including liquid biopsies and molecular profiling, improved early detection and treatment efficacy. This shift towards precision medicine facilitated more effective, individualized treatment strategies.

Technological progress, specifically the integration of next-generation sequencing and bioinformatics, facilitated the discovery of new therapeutic targets, enabling more effective drug design. Pharmaceutical companies, academic institutions, and government organizations increased their investments, supporting the development of innovative therapies. Initiatives such as the PanCAN grants program demonstrated a commitment to funding pancreatic cancer research, driving market growth.

The rising incidence of pancreatic cancer, influenced by lifestyle factors and an aging population, created a higher demand for specialized treatments. In 2024, Cancer Australia estimated 4,641 new pancreatic cancer cases were diagnosed in the country. This growing prevalence propelled market growth as healthcare providers sought more effective options. Furthermore, strategic collaborations between pharmaceutical companies and research institutions and regulatory support further accelerated market growth.

Pancreatic Cancer Precision Medicine Market Report Highlights:

  • Based on therapeutic approach, targeted therapy dominated the market and accounted for a share of 56.0% in 2024, owing to by advancements in personalized treatment and genomic profiling.
  • Chemotherapy-precision combinations, on the other hand, is expected to grow at the fastest CAGR of over the forecast period.
  • Based on diagnostic technology, genomic testing led the market and accounted for 40.8% in 2024. Its role in identifying actionable mutations proved essential for personalized treatment.
  • Liquid biopsies, a minimally invasive method for early detection via ctDNA and CTC analysis, are projected to grow at the fastest CAGR of 20.3% over the forecast period, driven by improved patient outcomes.
  • The increasing adoption of targeted therapies and immunotherapies, coupled with advanced diagnostics, fuels market growth by enhancing survival rates and tailoring effective precision medicine strategies.
  • North America dominated the global pancreatic cancer precision medicine industry with a 42.9% revenue share, driven by high incidence rates and demand for effective treatments.
  • Market players operating in the pancreatic cancer precision medicine industry include AstraZeneca; Pfizer Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd; PharmaCyte Biotech, Inc.; Genentech, Inc.; Guardant Health; Illumina, Inc.; Thermo Fisher Scientific Inc.; FOUNDATION MEDICINE, INC.
  • In August 2024, Illumina Inc. launched a new oncology menu for its NovaSeq X Series customers, expanding comprehensive genomic profiling at lower costs and greater scale for customers worldwide.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapeutic Approach
    • 1.2.2. Diagnostic Technology
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pancreatic Cancer Precision Medicine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Pancreatic Cancer Precision Medicine Market: Therapeutic Approach Business Analysis

  • 4.1. Therapeutic Approach Market Share, 2024 & 2030
  • 4.2. Therapeutic Approach Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Approach, 2018 to 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.5. PARP Inhibitors
    • 4.5.1. PARP Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. Monoclonal Antibodies
    • 4.6.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
  • 4.7. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
    • 4.7.1. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. Immunotherapy
    • 4.8.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.9. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
    • 4.9.1. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.10. Cancer Vaccines - GVAX, Algenpantucel-L
    • 4.10.1. Cancer Vaccines - GVAX, Algenpantucel-L Market, 2018 - 2030 (USD Million)
  • 4.11. Adoptive T-Cell Therapies - CAR-T Therapies
    • 4.11.1. Adoptive T-Cell Therapies - CAR-T Therapies Market, 2018 - 2030 (USD Million)
  • 4.12. Chemotherapy-Precision Combinations
    • 4.12.1. Chemotherapy-Precision Combinations Market, 2018 - 2030 (USD Million)
  • 4.13. Other Therapeutic Approaches
    • 4.13.1. Other Therapeutic Approaches Market, 2018 - 2030 (USD Million)

Chapter 5. Pancreatic Cancer Precision Medicine Market: Diagnostic Technology Business Analysis

  • 5.1. Diagnostic Technology Market Share, 2024 & 2030
  • 5.2. Diagnostic Technology Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Diagnostic Technology, 2018 to 2030 (USD Million)
  • 5.4. Genomic Testing
    • 5.4.1. Genomic Testing Market, 2018 - 2030 (USD Million)
  • 5.5. Molecular Diagnostics
    • 5.5.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.6. Liquid Biopsy
    • 5.6.1. Liquid Biopsy Market, 2018 - 2030 (USD Million)
  • 5.7. Biomarker-based Companion Diagnostics
    • 5.7.1. Biomarker-based Companion Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.8. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)
    • 5.8.1. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry) Market, 2018 - 2030 (USD Million)

Chapter 6. Pancreatic Cancer Precision Medicine Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AstraZeneca
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Pfizer Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Novartis AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Amgen Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bayer AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Eli Lilly and Company
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Teva Pharmaceutical Industries Ltd
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. PharmaCyte Biotech, Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Genentech, Inc.
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives
    • 7.5.12. Guardant Health
      • 7.5.12.1. Overview
      • 7.5.12.2. Financial Performance
      • 7.5.12.3. Product Benchmarking
      • 7.5.12.4. Strategic Initiatives
    • 7.5.13. Illumina, Inc.
      • 7.5.13.1. Overview
      • 7.5.13.2. Financial Performance
      • 7.5.13.3. Product Benchmarking
      • 7.5.13.4. Strategic Initiatives
    • 7.5.14. Thermo Fisher Scientific Inc.
      • 7.5.14.1. Overview
      • 7.5.14.2. Financial Performance
      • 7.5.14.3. Product Benchmarking
      • 7.5.14.4. Strategic Initiatives
    • 7.5.15. FOUNDATION MEDICINE, INC.
      • 7.5.15.1. Overview
      • 7.5.15.2. Financial Performance
      • 7.5.15.3. Product Benchmarking
      • 7.5.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global pancreatic cancer precision medicine market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 5 Global pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 6 North America pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 8 North America pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 10 U.S. Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 11 Canada pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 12 Canada pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 13 Mexico pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 14 Mexico pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 15 Europe pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 17 Europe pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 18 UK pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 19 UK Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 20 Germany pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 21 Germany pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 22 France pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 23 France Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 24 Italy pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 25 Italy pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 26 Spain pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 27 Spain pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 28 Norway pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 29 Norway Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 30 Denmark pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 31 Denmark pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 32 Sweden pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 33 Sweden pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 37 Japan pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 38 Japan pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 39 China pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 40 China pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 41 India pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 42 India pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 43 Australia pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 44 Australia pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 45 South Korea pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 46 South Korea pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 47 Thailand pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 48 Thailand pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 49 Latin America pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 51 Latin America pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 52 Brazil pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 53 Brazil pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 54 Argentina pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 55 Argentina pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 59 South Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 60 South Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 63 UAE pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 64 UAE pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
  • Table 65 Kuwait pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
  • Table 66 Kuwait pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pancreatic cancer precision medicine market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and diagnostic technology outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Pancreatic cancer precision medicine market dynamics
  • Fig. 12 Pancreatic cancer precision medicine market: Porter's five forces analysis
  • Fig. 13 Pancreatic cancer precision medicine market: PESTLE analysis
  • Fig. 14 Pancreatic cancer precision medicine market: Therapeutic approach segment dashboard
  • Fig. 15 Pancreatic cancer precision medicine market: Therapeutic approach market share analysis, 2024 & 2030
  • Fig. 16 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 17 PARP inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 18 Monoclonal antibodies market, 2018 - 2030 (USD Million)
  • Fig. 19 Small molecule inhibitors - EGFR inhibitors, KRAS inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 20 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 21 Immune checkpoint inhibitors - PD-1 inhibitors, PD-L1 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer vaccines - GVAX, Algenpantucel-L market, 2018 - 2030 (USD Million)
  • Fig. 23 Adoptive T-Cell therapies - CAR-T therapies market, 2018 - 2030 (USD Million)
  • Fig. 24 Chemotherapy-precision combinations market, 2018 - 2030 (USD Million)
  • Fig. 25 Other therapeutic approaches market, 2018 - 2030 (USD Million)
  • Fig. 26 Pancreatic cancer precision medicine market: Diagnostic technology segment dashboard
  • Fig. 27 Pancreatic cancer precision medicine market: Diagnostic technology market share analysis, 2024 & 2030
  • Fig. 28 Genomic testing market, 2018 - 2030 (USD Million)
  • Fig. 29 Molecular diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 30 Liquid biopsy market, 2018 - 2030 (USD Million)
  • Fig. 31 Biomarker-based companion diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 32 Others (Immunohistochemistry (IHC), proteomics, mass spectrometry) market, 2018 - 2030 (USD Million)
  • Fig. 33 Pancreatic cancer precision medicine market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 78 MEA pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework